Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro

Sorafenib and regorafenib administration is among the preferential approaches to treat hepatocellular carcinoma (HCC), but does not provide satisfactory benefits. Intensive crosstalk occurring between cancer cells and other multiple non-cancerous cell subsets present in the surrounding microenvironm...

Descripción completa

Detalles Bibliográficos
Autores principales: Dituri, Francesco, Scialpi, Rosanna, Schmidt, Tannin A., Frusciante, Martina, Mancarella, Serena, Lupo, Luigi Giovanni, Villa, Erica, Giannelli, Gianluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669886/
https://www.ncbi.nlm.nih.gov/pubmed/33199679
http://dx.doi.org/10.1038/s41419-020-03180-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669886/
https://www.ncbi.nlm.nih.gov/pubmed/33199679
http://dx.doi.org/10.1038/s41419-020-03180-8

Ejemplares similares